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6/j.bPretransplant donor treatment with immunomodulators such as complete Freund’s adjuvant (CFA) or oligo-
deoxynucleotide sequences expressing CpG motifs (CpG), was applied in sublethally irradiated host mice in-
oculated with murine models of mammary carcinoma (4T1) or B cell leukemia (BCL1). Spleen cells or IL-2
activated splenocytes (lymphokine activated killer [LAK]) derived from donor mice treated with CpG emul-
sified in incomplete Freund’s adjuvant (IFA), (CpG1 IFA) did not cause graft-versus-host disease (GVHD), but
were not efficient enough to induce a significant graft-versus-tumor (GVT) response against 4T1 cells. In con-
trast, an efficient graft-versus-leukemia (GVL) effect was evident in BCL1-bearing mice inoculated with spleen
cells from donors pretreated with CFA or CpG1 IFA. Pretransplant donor treatment with CFA prolonged
survival to a median of 62 days with 3 of 27 mice remaining GVHD- and leukemia-free for.200 days, com-
pared to GVHD-related death of all mice inoculated with naı¨ve cells (median 17 days), or leukemia-related
death of all mice inoculated with leukemia cells (median of 27 days). Pretransplant donor treatment with
CpG 1 IFA exerted a more efficient GVL effect with reduced GVHD resulting in 12 of 26 GVHD- and leu-
kemia-free survivors for.200 days. Our results suggest that it may be possible to prevent GVHD while spar-
ing an efficient GVL effect by using pretransplant donor treatment with immunomodulators prior to
allogeneic stem cell transplantation and/or donor lymphocyte infusions in hematologic malignancies.
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Themajor benefit of hematopoietic stem cell trans-
plantation (HSCT)and allogeneic cell therapy (alloCT)
is the induction of graft-versus-leukemia (GVL) or
graft-versus-tumor (GVT) effects. Unfortunately, the
alloreactivity directed against the host’s malignant cells
often causes a severe reaction against normal host cells,
known as graft-versus-host disease (GVHD) [1-6].rtment of Bone Marrow Transplantation & Cancer
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bmt.2008.12.504Although clinically significant, GVT effects may
occur without GVHD [7,8], other clinical observa-
tions have indicated a reduced incidence of malignant
relapse in patients with GVHD, reflecting the shared
biology between GVHD and antitumor activity
[9,10]. Because GVHD can develop into an uncon-
trolled life-threatening form, it has become an impor-
tant goal of many research and clinical studies to define
conditions in which GVL/GVT can be achieved with-
out manifestation of the irreversible harmful symp-
toms that occur in GVHD. Many potential ways to
separate these graft effects have been suggested and
tested including: T cell depletion, reduced intensity
conditioning (RIC), the use of defined cell subsets
such as T or allogeneic natural killer (NK) cells, elim-
ination of activated or antigen specific T cells, and ap-
plication of various biologic agents or pharmacologic
components that can modify the T helper (Th)1/Th2
balance and/or induce cellular and humoral immuno-
regulatory substances [11,12].
During the past decade, we have tried to enhance
the benefits of alloCT by various strategies directed
toward minimizing the risk of GVHD. We have
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eactive donor lymphocytes in the host mice prior to
HSCT resulted in significant GVL/GVT effects in
40% to 80% of the mice with no clinical GVHD symp-
toms [13,14]. Recently, we showed that pretransplant
donor treatment with immunomodulators such as com-
plete Freund’s adjuvant (CFA) or oligodeoxynucleotide
sequences expressing CpGmotifs (CpG), prevented the
development of GVHDefficiently in.77% ofmice in-
oculatedwith donor splenocytes following nonlethal to-
tal body irradiation (TBI) [15]. We, therefore, decided
to test this approach in tumor-bearing mice as part of
our attempts to control GVHD while sparing the anti-
malignancy activity of the allograft. In the current study
pretransplant donor treatment with CFA or CpG was
tested in a murine model of mammary carcinoma
(4T1) and B cell leukemia (BCL1) using spleen cells or
IL-2 activated splenocytes.MATERIALS AND METHODS
Mice
Female BALB/c H-2d (BALB), C57BL/6 H-2b (C57),
and (BALB/c  C57BL/6)F1 H-2d/b (F1) mice aged 10 to
12 weeks, weighing 22 to 24 g, were used in this study. All
mice were purchased from Harlan, Israel, and maintained
in the animal facility of the Hadassah University Hospital
in full compliance with the regulations for the protection
of animal rights.
Donor Pretreatment
CFA, incomplete Freund’s adjuvant (IFA) (Difco Labo-
ratories, Detroit, MI), 100 mg CpG (ODN #1826) or 100
mg non-CpG control (ODN #2138) (Coley Pharmaceutical
Group, Kanata, Canada) alone or as emulsions with IFA,
were injected subcutaneously (s.c.) into 2 sites in naive C57
mice (0.1 mL/site). Splenocytes were harvested 6 days
following CpG treatment or 10 days following CpG 1 IFA
and CFA treatment, based on previously reported data
concerning (1) number of spleen cells, (2) enriched
CD11b1GR-11 myelogenous suppressor cells, and (3) their
effect on GVHD inhibition [15,16].
Preparation of Lymphokine Activated Killer
(LAK) Cells
Naı¨ve or pretreated C57 splenocytes were cultured at
a concentration of 1.2  106/mL with 6000 IU/mL rhIL-2
(Proleukin, Chiron, Amsterdam, The Netherlands) in 1000
mL Lifecell bags (Nexell Therapeutics Inc, Irvine, CA) for
the preparation of LAK cells. The culture medium was
RPMI 1640 containing 2 mM glutamine, 100 mg/mL strep-
tomycin, 100 U/mL penicillin, 0.25 mg/mL amphotericin B,
1% minimal essential medium (MEM) nonessential amino
acids (Biological Industries, Beit Haemek, Israel), 10% fetal
bovine serum (FBS) (Invitrogen-GIBCO, Paisley, Scotland,
UK), and 5  1025 M 2-mercaptoethanol (Sigma-Aldrich,
Israel). Cells were harvested after 4 days in a 5% CO2
incubator at 37C.Tumor Cells
BCL1 is a spontaneous B cell leukemia/lymphoma of
BALB/c (H-2d) origin maintained by intravenous (i.v.) pas-
sage of blood from a tumor-bearing mouse [17]. 3B3 is
a cell line of BCL1 origin that grows in vitro as a cell suspen-
sion [18]. 4T1 is a tumor cell line established from a sponta-
neous mammary tumor of BALB/c (H-2d) origin [19]. 4T1
cells propagate in vitro as a monolayer and are harvested
by using 0.25% trypsin in 0.05% EDTA (Biological Indus-
tries, Beit Haemek, Israel). YAC-1(H-2a) is a lymphoma
cell line used as a target for testingNK activity in cytotoxicity
assays [20]. All cell lines were kept in a 5% CO2 incubator at
37C in RPMI 1640 medium containing 2 mM glutamine,
100 mg/mL streptomycin, 100 U/mL penicillin, 0.25 mg/
mL amphotericin B, 1% MEM nonessential amino acids,
and 10% FBS.
Experimental Design for GVHD Induction
F1 recipient mice were conditioned with 5.5 Gy TBI,
using a 6 MEV linear accelerator at a dose rate of 1.9 Gy/
min. These nonlethally irradiated recipients were inoculated
i.v. 48 hours later with 30 106 splenocytes or 20 106 LAK
cells from naı¨ve or pretreated C57 mice.
Chimerism Assay
Recipient mice were anesthetized (ketamine 100 mg/kg
and dihydrobenzperidol 1.2 mg/kg administered intraperito-
neally) and bloodwas taken from the retro-orbital sinus of the
eye. Peripheral blood mononuclear cells (PBMCs) were iso-
lated using lympholyte-M gradient (Cedar Lane Laborato-
ries, Ontario, Canada) and a percentage of donor cells was
detected by fluorescent-activated cell sorting (FACS) analysis
(see below) using phycoerythrin (PE) anti-H-2d antibodies
(BD Pharmingen, San Diego, CA). Following haploidentical
donor inoculation, the percentage ofH-2b donor cells was de-
terminedbymeasuring the disappearance of host cells carrying
H-2d antigen, according to the following formula: 100% 2
%H-2d positive cells5%H-2b positive cells.
Experimental Design for Induction of GVL and
GVT
F1 recipients were conditioned as for GVHD induction.
One day after irradiation, mice were inoculated i.v. with 5 
104 4T1 tumor cells or 104 BCL1 cells. Twenty-four hours
later mice were injected i.v. with 30 106 naı¨ve or pretreated
C57 splenocytes or 20  106 LAK cells from naı¨ve or pre-
treated C57 mice.
Magnetic Cell Sorting
Magnetic cell separation was carried out on suspensions
of splenocytes derived from either naı¨ve or pretreated C57
mice. T cells were isolated by depletion of non-T cells (neg-
ative selection) with the Mouse Pan T cell Isolation Kit
(MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). T
cell-depleted fractions (TCD) (negative selection) were
obtained by T cell depletion with mouse CD90 (Thy 1.2)
MicroBeads (MACS, Milteny Biotec, Bergisch Gladbach,
Germany). Phenotypic analysis of TCD isolated fraction
showed 0.6% CD31 cells and enrichment of CD11b1Gr-11
myeloid suppressor cells (15%). All isolations were carried
408 Biol Blood Marrow Transplant 15:406-415, 2009S. Morecki et al.out according to the manufacturers’ protocols. Briefly, for
isolated T cells and TCD fractions, splenocytes were labeled
with the corresponding antibody and then loaded onto
a MACS LS column, which was placed in the magnetic field
of a MACS Separator.
Adoptive Transfer (AT) Experiments
The 105 splenocytes from F1 recipients inoculated with
BCL1 and treated with either naı¨ve or pretreated C57 sple-
nocytes or LAK cells, were adoptively transferred i.v. into na-
ı¨ve BALB/c hosts 14 or 21 days after BCL1 inoculation, as
specified in each experiment.
Follow-up
In all experiments, mice were checked daily for the ap-
pearance of GVHD symptoms such as hunched posture, ruf-
fled fur, diarrhea, and cachexia, as assessed by weekly body
weight measurements. BCL1 leukemia was detected by
means of peripheral blood counts (data not shown) and
spleen enlargement. 4T1 lung metastases were detected in
postmortem examinations. Mice were checked for survival
over a follow-up period as specified in each experiment.
Cytotoxicity Test
Cytotoxicity was measured by the standard 51Cr release
assay as previously described [21]. Briefly, LAK cells from
naı¨ve or pretreated C57 mice were diluted to 5  106 cells/
mL and incubated for 4 h at different ratios with 5000 target
cell lines (4T1, 3B3, or YAC-1) already labeled for 1 hour
with 51Cr sodium chromate (GE Healthcare-Amersham,
UK). Percentage of cytotoxicity was calculated by the follow-
ing formula: (cpm of sample2 cpm of spontaneous release)/
(cpm of target cells treated with 1% Triton 2 cpm of spon-
taneous release)  100.
Flow Cytometry Analysis
For FACS analysis, cells were stained with the following
antibodies: PE Pan NK cells (DX5) to detect CD49b1 cells,
fluorescein isothiocyanate (FITC) anti-mouse-CD3 and al-
lophycocyanin (APC) antimouse-CD8a to detect T cells
(BD-Pharmingen, San Diego, CA).
Prior to fluorescein staining, splenocytes were lysed with
mouse erythrocyte lysing buffer (R&D Systems, Mineapolis,
MN). Fluorescein staining was carried out as follows: 5 105
splenocytes were incubated for 5 minutes with mouse Fc
blocker (CD32/16) antibody (eBioscience, San Diego, CA)
to prevent nonspecific staining, subsequently stained with
the relevant antibodies for 20 minutes in ice, washed with
1% bovine serum albumin (BSA), 0.03% azide in phos-
phate-buffered saline (PBS), and resuspended in PBS for
reading. Samples were analyzed with BDFACSCalibur using
the Cell Quest program (BD, San Diego, CA).
Statistical Analysis
The Kaplan-Meier method was used to calculate the
probability of tumor-free survival, a function of time after
cell or tumor inoculation [22]. The statistical significance
between Kaplan-Meier curves was evaluated using the
Log-rank test [23]. The statistical significance of cytotoxicassays, phenotypic analysis, and body weight was evaluated
by the standard 2-tailed, unpaired Student’s t-test.RESULTS
Effect of CpG1 IFADonor Treatment onGVHD
Induced by LAK Cells
Splenocytes fromCpG1 IFA-treated donors were
incubated in vitro with IL2 and checked for their cyto-
toxic activity against NK sensitive target cells (YAC-1)
or NK-resistant cells such as mammary carcinoma
4T1 cells and B cell leukemia cells (BCL1). Following
incubation, the total cell yield of LAK cultures derived
from CpG 1 IFA-treated donors was 40% less than
the cell yield obtained from naı¨ve donors (data not
shown). As seen in Figure 1a, cytotoxic activity of
LAK cells derived from CpG 1 IFA-treated donors
was lower than that of LAK cells from naı¨ve or non-
CpG 1 IFA-treated mice when tested against YAC-1
cells (22% versus 40% and 39%, respectively) or
against BCL1 cells (12% versus 34% and 22%, respec-
tively). Cytotoxicity against 4T1 cells was almost the
same for all 3 cell sources (23% versus 25% and
27%, respectively).
Phenotypic analysis of LAK cells from CpG 1
IFA-treated donor’s shows the same frequency of
CD31 or CD81 cells as naı¨ve LAK cells, a nonsignifi-
cant increase in CD11b1Gr-11 cells, and a slight
significant reduction of NK1.11 cells, compared to
naı¨ve LAK cells (Figure 1b). Following LAK genera-
tion, the phenotypic changes induced by CpG 1 IFA
treatment in the spleen are no longer fully maintained
(Figure 1c), and distribution of the LAK cell subset
population is fairly similar to that of the LAK cell
subset population identified in naı¨ve cells.
The differentially reduced LAK activity in vitro led
us to test its correlation to the ability to induce GVHD
and to exert GVL/GVT effects in vivo. A murine
model of GVHD was set up and LAK cells from
CpG 1 IFA-treated C57 donor mice were inoculated
into sublethally irradiated F1 host mice. As shown in
Figure 2, naı¨ve C57-derived LAK cells caused marked
GVHD-related body weight loss of about 4 g over 10
days. A similar body weight loss was also seen in F1
host mice inoculated with LAK cells derived from
splenocytes of C57 mice pretreated with IFA, CpG
alone, non-CpG, or non-CpG 1 IFA. In contrast,
donor-derived LAK cells prepared fromC57mice pre-
treated with CpG emulsified in IFA, did not induce
GVHD-related symptoms such as hunched posture,
ruffled fur, or cachexia as assessed by serial measure-
ments of body weight. All control groups of mice inoc-
ulated with donor cells treated with IFA, CpG alone,
non-CpG, non-CpG emulsified in IFA, or naive donor
cells, died of severe GVHD in a median of 10 to
14 days following LAK cell inoculation. Of 29 mice
Figure 2. Effect of LAK cells derived from CpG-treated donor mice on
GVHD induction, as measured by body weight. Sublethally (5.5 Gy) irra-
diated (BALB  C57) F1 mice were inoculated with 20  106 LAK cells
derived from either naı¨ve or CpG- or non-CpG-treated C57 donor
mice 6 days before spleen harvest, and CpG 1 IFA- or non-CpG 1
IFA-treated C57 donor mice 10 days before spleen harvest. Results rep-
resent 1 of 2 experiments. P\.012 for the comparison of body weight
on day 10 following donor treatment with CpG 1 IFA versus donor
treatment with CpG, non-CpG, non-CpG 1 IFA, IFA, or no treatment
of naı¨ve donor splenocytes.
Figure 1. Cyotoxic activity and phenotypic analysis of LAK cells derived from CpG1 IFA-treated donors. Splenocytes were harvested from C57 naı¨ve
mice or mice treated with non-CpG1 IFA or CpG1 IFA 10 days previously and incubated with rIL-2 for 4 days. Cytotoxicity (A) was tested by 51Cr
release assay. Results are presented as mean of % specific lysis 6 SE measured at a 25:1 cell ratio of effector: target. P 5 .001 for the comparison of
cytotoxicity directed to 3B3 cells by LAK cells derived from naı¨ve versus CpG1 IFA-treated donors. Results represent 1 of 2 experiments. Phenotypic
analysis (B) was carried out by using flow cytometry. Data were pooled from 3 experiments, and results are presented as mean of % positive cells6 SE.
P5 .014 for the comparison of %NK1.11 LAK cells following CpG1 IFA donor treatment versus %NK1.1 1 in LAK cells derived from naı¨ve mice. P\
.001 for the comparison of %NK1.11 , %CD11b1GR-11, %CD81, and %CD31 in splenocytes versus LAK cells derived from mice treated with
CpG1IFA (C).
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treated with CpG emulsified in IFA, 18 mice survived
GVHD-free for .200 days (Table 1). It is worth not-
ing that these mice retained the H-2b donor-derived
LAK cells for .80 days following LAK inoculation
(Table 2).Effect of CpG-Treated Donor LAK Cells on GVT
Response
Sublethally irradiated F1mice inoculated with 4T1
mammary carcinoma cells were treated with allogeneic
LAK cells. LAK cells derived either from naı¨ve C57
mice or from C57 mice treated pretransplant with
IFA or non-CpG 1 IFA caused severe GVHD, which
led to the death of all host mice in a survival median of
17, 13, and 13 days, respectively. In contrast, LAK cells
from donors treated pretransplant with CpG 1 IFA,
did not cause GVHD, but almost all the hosts died
of tumor between days 24 and 60, with a median of
27 days, the same as hosts inoculated with tumor cells
only (Table 3). Overall, no statistically significant
difference was observed in a comparison of hosts
Table 1. Effect of Pretransplant Donor Treatment with CpG
on GVHD Induction by LAK Cells
Donor
Pretreatment
Survival (Days) GVHD-
Related
Death
Disease-
Free
SurvivorsMedian (Range) n
— 12 (7-21) 30 30 0
IFA 14 (7-17) 27 27 0
CpG 11 (7-14) 11 11 0
non-CpG 10 (10-13) 9 9 0
CpG + IFA >200 (10->200) 29 11 18
non-CpG + IFA 13 (7-17) 14 14 0
GVHD indicates graft-versus-host disease; CpG, CpG motifs; LAK, lym-
phocyte-activated killer cell.
Sublethally irradiated (5.5 Gy) (BALB/cXC57BL/6) F1 mice were inocu-
lated i.v. with 20  106 C57BL/6 LAK cells 48 hours following irradia-
tion. LAK cells were prepared by 4 days’ IL-2 activation of splenocytes
derived from either naı¨ve or donor mice inoculated s.c. 10 days previ-
ously with IFA, IFA + CpG or non-CpG + IFA. CpG and non-CpG
were injected s.c. 6 days before spleen harvesting. P < .001 for compar-
ison of CpG + IFA with each of the experimental groups. Data of un-
treated donor controls were collected from 5 experiments; CpG and
non-CpG were collected from 2 experiments, and all the rest from 3
experiments.
410 Biol Blood Marrow Transplant 15:406-415, 2009S. Morecki et al.inoculated with LAK cells from naı¨ve donors and LAK
cells from IFA or non-CpG 1 IFA-treated donors
(P . .143). Survival of host mice inoculated with
LAK cells from CpG1 IFA-treated donors was statis-
tically different from survival of mice inoculated with
naı¨ve LAK cells (P \ .001), but was not different
from untreated mice that were inoculated with 4T1
cells only (P 5 .218). The results showed that alloCT
with LAK cells from CpG 1 IFA-treated donors pre-
vented GVHD induction but was not efficient enough
to induce a GVT response in an experimental model of
mammary carcinoma.Table 3. Effect of LAK Cells Derived from CpG-Treated
Donors on Graft versus Mammary Carcinoma Cells (4T1)
Donor C57 Survival GVHD- Tumor- Disease-The Effect of CFA- and CpG-Treated Donor
Splenocytes on GVT
The use of LAK cells as effector cells did not lead
to a significant number of tumor- and GVHD-free
survivors in 4T1 tumor-bearing mice. Therefore, weTable 2. Induction of Chimerism by CpG + IFA Pretransplant
Donor Treatment
Donor Cell
Source*
% Donor
Cells (H-2b)†
Mean ± SD n
Spleen cells 96 ± 4 16
LAK cells 88 ± 11 12
CpG indicates CpG motif; IFA, incomplete Freund’s adjuvant; LAK, lym-
phocyte killer.
*Splenocytes derived from C57BL/6 donor mice treated with CpG + IFA
10 days previously, were inoculated into F1 sublethally irradiated (5.5
Gy) mice. LAK cells were prepared by incubation of spleen cells with
rIL-2 for 4 days before inoculation into F1 sublethally irradiated mice.
†% donor cells was determined by FACS analysis on day 80 following cell
inoculation (see Material and Methods). Data were collected from 2 sep-
arate experiments.tested the GVT effect exerted by nonactivated spleen
cells from donor mice that were treated pretransplant
with various immunomodulators.
Donor treatment with CFA orCpG alone or emul-
sified in IFA resulted in delayed tumor-related death
(median of 47, 43, and 42 days, respectively) of F1
host mice that were inoculated with 4T1 cells and
C57 pretransplant-treated donor splenocytes (Table
4). The control group of mice inoculated with 4T1
only died of tumors in a median of 32 days, and the
control group of mice given naı¨ve C57 donor cells
died mainly of GVHD in a median of 13 days. Despite
the statistically significant difference between controls
and experimental groups of mice inoculated with pre-
transplant-treated splenocytes, the donor treatment
led to a moderate GVT effect. The best pretransplant
donor treatment was CFA, which resulted in 11% (6 of
52) of disease-free survivors (DFS) over a follow-up
period of 250 days.The Effect of CpG-Treated Donor LAK Cells on
GVL Response
Sublethally irradiated F1 mice inoculated with
BCL1 cells were treated with allogeneic LAK cells de-
rived from either naı¨ve C57 mice or C57 mice treated
with non-CpG 1 IFA or CpG 1 IFA. All mice devel-
oped severe GVHD and died between days 10 and 17
(data not shown). Adoptive transfer of splenocytes
harvested from these LAK-treated hosts on day 14
following tumor inoculation, revealed that all the
LAK-treated hosts, including hosts treated with naı¨ve
or pretransplant-treated donor cells, exerted a strong
and efficient GVL effect for 14 days. None of
the secondary hosts inoculated with the adoptivelyPretreatm
ent
LAK
Cells
Related
Death
Related
Death
Free
SurvivorsMedian (Range) n
2 2 27 (24-27) 5 5 0
2 + 17 (12-17) 7 7 0 0
IFA + 13 (12-17) 9 9 0 0
CpG + IFA + 27 (24-60) 9 1 8 0
Non-CpG +
IFA
+ 13 (12-17) 9 9 0 0
GVHD indicates graft-versus-host disease; LAK, lymphokine activated
killer; IFA, incomplete Freund’s adjuvant; CpG, CpG motif.
Sublethally (5.5 Gy) total-body irradiation [TBI]) (BALB/cXC57BL/6)
F1 mice were inoculated i.v. with 5  104 4T1 cells 1 day following
TBI. Twenty-four hours later, 20 106 C57BL/6 LAK cells were injected
i.v. LAK cells were prepared by 4 days’ IL-2 activation of splenocytes
from either naı¨ve donors or donors inoculated s.c, 10 days previously
with IFA, CpG + IFA or non-CpG + IFA. P < .001 for the comparison
of CpG + IFA-treated donors versus naı¨ve donors, or IFA or non-
CpG + IFA-treated donors. P 5 .218 for the comparison of CpG +
IFA-treated donors versus mice inoculated with 4T1 only. Data was col-
lected from 1 experiment.
Table 4. The Effect of Donor-Treated Splenocytes on Mam-
mary Carcinoma Cells
Experi
mental
Group
Donor
Pretreatm
ent
C57
Splenocytes
Survival (Days) GVHD-
Related
Deaths
Tumor-
Related
Deaths
Disease-
Free
SurvivorsMedian (Range) n
a 2 2 31 (18-47) 28 28 0
b 2 + 13 (10-59) 25 23 2 0
c CFA + 47 (11->250) 52 10 36 6
d CpG + 43 (28-95) 11 6 5 0
e non-CpG + 13 (11-18) 11 10 1 0
f CpG +
IFA
+ 42 (24->250) 27 11 15 1
g non-CpG
+ IFA
+ 23 (14->250) 18 13 3 2
GVHD indicates graft-versus-host disease; LAK, lymphocyte killer; IFA,
incomplete Freund’s adjuvant; CpG, CpG motif.
Sublethally irradiated (5.5 Gy) (BALB/C  C57 Bl/6) F1 mice were inoc-
ulated i.v. with 5  104 4T1 tumor cells 1 day following irradiation.
Twenty-four hours later, naı¨ve, CFA, CpG, or CpG + IFA-treated
C57BL/6 donor splenocytes (30  106) were inoculated i.v. Unless oth-
erwise noted, all donor treatments were given s.c. 10 days before spleen
harvesting. CpG and non-CpG were given to donor mice 6 days before
harvesting. Data were collected from 5 experiments for groups a, b,
and c, 1 experiment for groups d and e, and 3 experiments for groups
f and g. P < .001 for the comparison of control of tumor only versus
donor pretreatment with CFA, CpG, or CpG + IFA. P > .05 for the
comparison of CFA versus CpG or CpG + IFA and for the comparison
of CpG versus CpG + IFA. P < .05 for the comparison of CpG versus
non-CpG and P > .05 for the comparison of CpG + IFA versus non-
CpG + IFA.
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follow-up period of .200 days (Table 5).
The Effect of CFA-Treated Donor Splenocytes
on GVL
F1 mice inoculated with BCL1 cells and treated
with allogeneic C57 splenocytes from mice previously
treated with CFA, survived for a median of 62 days fol-
lowing leukemic cell inoculation in comparison with
a survival median of 17 days for mice inoculated with
naı¨ve C57 spleen cells or a survival median of 27Table 5. Effect of LAK Cells Derived from CpG-Treated Do-
nors on Leukemia Cells (BCL1) in Adoptive Transfer (AT)
Experiments
C57
LAK
Donor
Pretreatment
Survival (Days)
Tumor-Related
Deaths
Disease-Free
SurvivorsMedian (Range) n
2 2 31 (28-63) 7 7 0
+ 2 >200 7 0 7
+ CpG + IFA >200 7 0 7
+ non-CpG + IFA >200 6 0 6
LAK indicates lymphocyte killer; IFA, incomplete Freund’s adjuvant;
CpG, CpG motif.
The 105 splenocytes were adoptively transferred into naı¨ve secondary
BALB hosts 14 days following BCL1 inoculation into sublethally (5.5
Gy) irradiated (BALB  C57) F1 mice that were treated with C57
LAK cells derived from either naı¨ve or CpG + IFA pretreated donor
mice. CpG + IFA and non-CpG+ IFA were inoculated s.c. 10 days before
spleen harvesting. Data represent 1 experiment. P < .001 for the com-
parison of each experimental group versus group of mice inoculated
with BCL1 only without cell therapy.days for control mice inoculated with BCL1 only.
Three of a total of 27 F1 mice inoculated with C57
splenocytes fromCFA-treatedmice wereDFS without
any evidence of GVHD or leukemia for .200 days
(Figure 3). Evidence of a GVL effect was seen in AT
experiments in which CFA pretreated spleen cells
taken 14 or 21 days following tumor inoculation did
not cause leukemia in any of the new hosts for a fol-
low-up period of .230 days. In contrast, AT of sple-
nocytes taken 14 or 21 days following tumor
inoculation from control mice inoculated with BCL1
cells only (Table 6), led to onset of leukemia, and all
these mice died of leukemia in a median of 42 and 24
days, respectively. It is worth noting that AT of spleno-
cytes taken on day 14 from mice inoculated with naı¨ve
spleen cells did not cause leukemia in the secondary
hosts. AT on day 21 following tumor inoculation could
not be carried out, because by that time all the mice in-
oculated with naı¨ve cells had died. In summary, our re-
sults showed an apparent advantage of CFA- donor
spleen cells over naı¨ve donor cells in exerting a GVL
effect.
The Effect of CpG-Treated Donor Splenocytes
on GVL
Spleen cells from naı¨ve or CpG-treated C57 mice
were injected into sublethally irradiated F1 mice that
were inoculated with BCL1 cells (Figure 4). Almost
all mice inoculated with naı¨ve splenocytes died of
severe GVHD in a median of 19 days, whereas CpG
pretreated splenocytes significantly prolonged survival
up to a median of 64 days. It is worth noting that most
of these F1 host mice died of late GVHD (10 of 13) and
only 3 of 13 died of leukemia (Figure 4A). C57 spleno-
cytes from CpG 1 IFA-treated mice exerted a muchFigure 3. Effect of splenocytes from CFA-treated donors on GVL. Sub-
lethally (5.5 Gy) irradiated (BALB  C57) F1 mice were inoculated with
104 BCL1 cells 24 hours following irradiation. One day later, naı¨ve or
CFA pretreated C57 splenocytes were injected i.v. CFA was inoculated
s.c. into C57 donor mice (200 mL) 10 days before spleen harvesting. Data
was pooled from 3 experiments. P\.001 for the comparison of treat-
ment with CFA-C57 cells versus BCL1 only and naı¨ve C57 cell treat-
ment.
Table 6. Effect of Pretransplant Donor Treatment with CFA
on Leukemia Cells (BCL1) in Adoptive Transfer (AT) Experi-
ments
C57
Splenocytes CFA
Day of AT
after BCL1
Inoculation
Survival (Days) Tumor-
Related
Death
Disease-
Free
SurvivorsMedian (Range) n
2 2 14 42 (23-61) 12 12 0
+ 2 14 >230 12 0 12
+ + 14 >230 11 0 11
2 2 21 24 (16-48) 12 12 0
+ 2 NA* NA NA NA
+ + 21 >230 13 0 13
CFA indicates complete Freund’s adjuvant; GVHD, graft-versus-host
disease.
The 105 splenocytes were adoptively transferred into naı¨ve secondary
BALB hosts 14 or 21 days following BCL1 (104) inoculation into sublethally
(5.5 Gy) irradiated (BALBC57) F1 mice that were treated with naı¨ve or
CFA pretreated C57 splenocytes. CFA was inoculated s.c. into C57 donor
mice (200 mL), 10 days before spleen harvesting. P < .001 for the compar-
ison of each experimental group versus group of mice inoculated with
BCL1 only without cell therapy. Data represent 1 experiment.
*NA 5 mice treated with naı¨ve C57 splenocytes died of acute GVHD
before the ATexperiment on day 21.
412 Biol Blood Marrow Transplant 15:406-415, 2009S. Morecki et al.more significant GVL effect and prolonged survival
time up to a median of 166 days, with 12 of 26 dis-
ease-free F1 host mice surviving for.200 days follow-
ing BCL1 inoculation. Only 3 of 26 F1 host mice died
of late leukemia (between days 101 and 122), 4 of 26
died of GVHD between days 14 and 49, and 7 of 26
mice died of late GVHD (between days 66 and 172)
in this experimental group (Figure 4B). In 6 of 6
mice taken as a sample from the 12 of 26 DFS mice,
.95% C57 donor cells were present on day 100 fol-
lowing cell inoculation (data not shown).
In an attempt to overcome the late GVHD-related
death observed in BCL1 inoculated mice, we designed
another protocol to achieve more efficient removal of
BCL1 cells while ensuring that the presence of the
BCL1 cells would not neutralize the benefit of
pretransplant donor treatment with CpG 1 IFA.Figure 4. Effect of Splenocytes from CpG-Treated Donors on GVL. Subletha
BCL1 cells 24 hours following irradiation. On the day after, mice were injected i
pretreated 6 days previously with CpG, or non-CpG (A); or from mice pretrea
treatments were carried out by s.c. inoculation (100 mg). Data were pooled fr
versus non-CpG, for the comparison of CpG 1 IFA versus non-CpG1IFA anAccordingly, mice inoculated with a lethal dose of
BCL1 cells were treated with splenocytes from C57
donor mice pretreated with CpG 1 IFA or with its
control of non-CpG1IFA. Eight days later, mice
were injected with C57 naı¨ve T cells plus TCD cell
fraction of splenocytes derived from C57 donors pre-
treated 10 days previously with either CpG 1 IFA or
with its control nonCpG 1 IFA. As seen in Figure 5,
the addition of naı¨ve T cells 1 TCD splenocytes did
not allow leukemia to develop, but 5 of 9 mice died
of late GVHD (between days 62 and 146). The re-
maining 4 of 9 mice were DFS for .200 days with
full donor chimerism (data not shown). Control
groups of mice treated with C57 naı¨ve splenocytes
only, or inoculated with 2 treatments of non-CpG 1
IFA derived cells, died of acute GVHD (aGVHD) in
a median of 16 and 23 days, respectively (Figure 5).
The addition of a second cycle of cell therapy consist-
ing of naı¨ve T cells1TCD fraction following CpG1
IFA treatment was not statistically different (P . .05)
from 1 cycle of treatment with whole spleen cells
following CpG 1 IFA. Overall, our results show the
efficacy of CpG 1 IFA donor treatment in inducing
a GVL response, and the ability to maintain a large
part of the experimental group GVHD- and leuke-
mia-free for a long time.DISCUSSION
Pretransplant donor treatment with immunomod-
ulators that enables efficient prevention of GVHDwas
tested for its ability to exert GVL/GVT effects.
Donor treatment with CpG 1 IFA efficiently pre-
vented GVHD induced by parental LAK cells inocu-
lated into sublethally irradiated F1 mice. A detailed
phenotypic analysis of splenocytes derived from micelly (5.5 Gy) irradiated (BALB  C57) F1 mice were inoculated with 104
.v. with 30 106 C57 splenocytes derived from naı¨ve mice, or from mice
ted 10 days previously with CpG1 IFA or non-CpG1 IFA (B). All pre-
om 2 experiments. P\.001 for the comparison of treatment with CpG
d for the comparison of CpG 1 IFA versus CpG.
Figure 5. Effect of T cell-depleted splenocytes (TCD) from CpG-
treated donors on GVL. Sublethally (5.5 Gy) irradiated (BALB  C57)
F1 mice were inoculated with 10
4 BCL1 cells 24 hours following irradi-
ation. One day later, mice were injected i.v. with 30  106 C57 spleno-
cytes derived from either naı¨ve mice or from mice pretreated 10 days
previously with CpG 1 IFA or non-CpG 1 IFA. Eight days later, the
last 2 groups received either C57 naı¨ve T cells (3  106) together
with TCD splenocytes (35  106) from CpG 1 IFA-treated donors
or C57 naı¨ve T cells together with TCD splenocytes from non-CpG
1 IFA-treated donors. All pretreatments were carried out by s.c. inoc-
ulation (100 mg). Data represent 1 experiment. P\.002 for the compar-
ison of CpG1 IFA treatment versus naı¨ve control of BCL1 only and P\
.001 for the comparison of CpG 1 IFA versus non-CpG 1 IFA treat-
ment.
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effect on GVHD induction across semiallogeneic or
fully mismatched allogeneic barriers, was previously
reported by us [15,16]. Inoculation of splenocytes or
LAK cells following CpG 1 IFA treatment resulted
in efficient engraftment, as evidenced by the high per-
centage of donor cells present in peripheral blood sam-
ples taken .80 days following cell inoculation. This
rules out the possibility that the absence of GVHD is
because of donor cell rejection. Although pretrans-
plant donor treatment with CpG alone prevented sple-
nocyte-induced GVHD in 89% of the mice [15], it did
not prevent severe GVHD induced by LAK cells. This
might be related to our recent reports [16] showing the
higher enrichment of myelogenous CD11b1Gr-11
suppressor cells achieved following treatment of
CpG 1 IFA compared to donor treatment with CpG
alone. These CD11b1Gr-11 cells were elevated as
well following CFA treatment [15]. It is worth noting
that following IL-2 activation of CpG 1 IFA pre-
treated splenocytes (LAK), there was a reduction in
these myelogenous cells accompanied by an increase
in CD31, CD81 CD161, and NK1.11 cells. These
enriched cell subsets were previously identified byothers in naı¨ve LAK cells [24] .The phenotypic
changes incurred can explain their reduced protective
effect against GVHD induction following inoculation
of CpG 1 IFA-treated LAK cells (our current manu-
script) versus inoculation of CpG 1 IFA-treated sple-
nocytes [15]. Because no changes in CD41CD251 or
CD31CD561 cells were observed following CpG 1
IFA treatment, immunomodulation by CpG 1 IFA
treatment could not be ascribed to these T regulatory
or NKT cells [15].
To test the effect of pretransplant donor treatment
on the induction of GVL and GVT responses, alloCT
was carried out in mice inoculated with BCL1 or 4T1
cells, respectively. The GVL effect was tested by means
of AT experiments carried out 14 days following leuke-
mia (BCL1) inoculation. No evidence of residual leuke-
mic cells was detected in the secondary hosts following
injection of spleen or LAK donor cells derived from na-
ı¨ve mice or mice pretreated with immunomodulators.
The advantage of pretransplant donor treatment with
immunomodulators became apparent when AT was
carried out on day 21; at that time, none of the mice
treated with naı¨ve splenocytes were alive and available
for AT, whereas spleen cells from CFA-treated donor
mice were available for transfer and did not cause leuke-
mia in any of the naive secondary hosts for.200 days of
follow-up. Despite the long-lasting efficacy of pretrans-
plant donor treatment to prevent GVHD in mice that
were not inoculated with tumor cells, in the presence
of BCL1, a number of the primary host mice developed
late GVHD. In contrast tomanymalignant cells, BCL1
cells express major histocompatibility (MHC) class I
and II antigens on their surface as well as the costimula-
tory B-7 molecule, which is critical for the induction of
an immune reaction [25,26]. Residual BCL1 cells that
may have survived the aGVHDwhile not causing leuke-
mia in the primary hosts, may have served as antigen-
presenting cells (APCs), which present host MHC
alloantigens to donor cells, thereby leading to the devel-
opment of late GVHDwhen themyelogenous suppres-
sor cells from the CpG1 IFA-treated donor no longer
exist to exert their suppressive activity. In accordance
with this, it is worth noting that BCL1 cells, unlike
other malignant B cells, are good stimulators in mixed
lymphocyte reactions (MLRs) in vitro (data not shown)
probably because of the expression of the important
molecules necessary for efficient T cell activation. We
attempted to prevent late GVHD by removing leuke-
mia cells more efficiently with a second cycle of cell
therapy: naı¨ve T cells given together with myelogenous
suppressor cells (TCD fraction derived from CpG 1
IFA-treated donors), were administered a week after
the first dose of alloCT. Unfortunately, late GVHD
still developed in some of the mice, which suggests
that the second cycle of cell therapy, consisting of the
naı¨ve T cells 1 TCD fraction, should be given after
a longer time lapse.
414 Biol Blood Marrow Transplant 15:406-415, 2009S. Morecki et al.Although no apparent GVT effect was achieved
following CpG 1 IFA donor treatment, the spleno-
cytes had a slight advantage over the LAK-derived
cells. This might be because of the different cell subset
population identified by phenotypic analysis, longer
survival of the splenocytes exerting the GVT effect,
as well as the possibility that the GVT effect required
a specific effector mechanism as opposed to the non-
specific killing effect provided by the LAK cells.
The ability to achieve a GVL effect with no appar-
ent GVT effect might be explained by the fact that leu-
kemia cells (eg, BCL1) circulate systemically and are
therefore more easily accessible to donor cells than lo-
cally residing solid tumors (eg, 4T1 cells). The differ-
ence might also be related to the type and/or source of
the targeted malignant cells, for example, hematopoi-
etic cells versus cells of epithelial origin. The GVL ef-
fect was not a result of direct cytotoxicity, as can be
seen from the significantly reduced cytotoxic activity
of CpG 1 IFA-treated LAK cells against leukemic
cells (3B3), compared to their unchanged cytotoxicity
against 4T1 cells. Pretransplant donor treatment
with immunomodulators significantly reduced the
number of mice that died of GVHD compared to naı¨ve
or non-CpG-treated donors, but the majority of mice
inoculated with 4T1 cells died of tumor, as opposed to
BCL1 inoculated mice that died mainly of late
GVHD. The discrepancy between GVL and GVT ef-
fects might possibly reflect the differential capability of
an effector mechanism, which is able to prevent leuke-
mia development, but is not activated bymalignant ep-
ithelial cells. Generally, and in accordance with our
observations, donor lymphocyte infusion (DLI) and
HSCT aiming to exert a graft-versus-malignancy ef-
fect, have proved to be a treatment of choice for a num-
ber of hematologic malignancies, whereas there have
been fewer reported cases of solid tumors in experi-
mental models and clinical trials [14,27-33]. The dis-
parity in the efficacy of alloCT directed against
hematopoietic malignant cells versus carcinoma cells
is confusing, and needs further intensive investigation.
CpG has been administered as an adjuvant to stim-
ulate a Th1-type response [34], but it has also been
able to mediate an anti-inflammatory response and to
confer protection from arthritis through a T cell-inde-
pendent increased level of interferon (IFN)-g [35].
A similar model of action might play a role in the
CpG immunomodulatory effect observed in our ex-
periments, as shown by the elevated IFN-g level de-
tected following CpG 1 IFA treatment [16].
Pretransplant donor treatment with CpG 1 IFA
was more effective than treatment with CFA for induc-
tion of long-lasting GVL effects. This finding gives
our strategy of pretransplant donor treatment with
immunomodulators a legitimate rationale for future
clinical application. Replacing the mycobacterium
component in the CFA with CpG allows for saferuse and avoidance of the toxic granulomatous reaction
that occurs following injection of this adjuvant [36].
Previously, we reported and discussed the advantage
of pretransplant donor treatment over host treatment
in preventing GVHD [15,16]. Now, we have tested
the antileukemia response in our strategy of pretrans-
plant donor treatment in inducing the antileukemia ef-
fect. Indeed, we have demonstrated that regulation of
allogeneic response in GVHD, while sparing a GVL
effect, could be achieved in a significant number of
mice inoculated with pretransplant-treated donor
splenocytes. The ability to achieve a GVL effect with-
out GVHD was especially obvious in a significant
number of mice for at least 100 days following alloCT.
We could not ascribe an essential role to NK cyto-
toxicity in our experimental model, and the major ef-
fect of pretransplant donor treatment with CpG in
our study was the enrichment of the CD11b1GR-
11cells, which successfully control an allogeneic reac-
tion in the host within a narrow time window, when
only a few leukemic cells are present. Similar to our
previous [15,16] and current findings, a recent study
showed that the CpG immunoregulatory activity was
not mediated via NK cells but rather by activation of
APCs, especially CD11b1 cells, when CpG was given
to the host in a murine bone marrow transplantation
model [37]. The allogeneic reaction, ensued under
the CpG immunomodulatory activity, facilitated the
prevention of severe systemic GVHD on 1 hand and
simultaneously inhibited leukemia cell propagation ef-
ficiently in a state of minimal leukemia disease.
Because of the controversial issue of whether GVL/
GVT effects can be achieved without concomitant in-
duction of GVHD and the fact that a clean separation
of GVL effects fromGVHD has been achieved only in
a minority of experimental models [8,12,38-41], our
findings are of crucial importance. This should en-
courage further attempts to strive toward more effec-
tive cell therapy by alloreactive lymphocytes to
improve the outcome of allogeneic stem cell transplan-
tation in patients with hematologic malignancies.ACKNOWLEDGMENTS
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